Actelion Wins European Approval for Pulmonary Arterial Hypertension Drug
Posted on: Tuesday, 5 August 2008, 06:00 CDT
Actelion has announced that Tracleer, a dual endothelin receptor antagonist, has been approved in the European Union for the treatment of patients with mildly symptomatic pulmonary arterial hypertension.
Tracleer is claimed to be the first pulmonary arterial hypertension (PAH) treatment ever to be investigated in a clinical study that exclusively enrolled patients with mildly symptomatic pulmonary arterial hypertension. This 185-patient randomized, double-blind, placebo-controlled study called EARLY (Endothelin Antagonist tRial in miLdlY symptomatic PAH patients) provided the basis for this EU approval.
Jean-Paul Clozel, CEO of Actelion, said: "Our dual endothelin receptor antagonist Tracleer is the only PAH medicine to have demonstrated a delay in disease progression in three independent placebo-controlled, randomized clinical studies. Actelion will now communicate these important clinical findings to encourage early diagnosis and intervention."
Source: Datamonitor
Related Articles
- Biomarkers Could Help Predict Risk Of Alzheimer's Disease In Patients With Mild Cognitive Impairment
- Horizon Therapeutics' HZT-501 Significantly Reduces Incidence of NSAID-Induced Upper Gastrointestinal Ulcers in Patients With Mild-to-Moderate Pain
- Incyte's Topical JAK Inhibitor Demonstrates Positive Proof-of-Concept Results in Patients With Mild to Moderate Psoriasis
- Pivotal Pulmonary Arterial Hypertension Study Published in The Lancet Concludes That Bosentan (Tracleer(R)) Demonstrates Benefits in Patients With Mildly Symptomatic WHO Functional Class II Disease
- 500,000 Patients Treated at Take Care Health Clinics
- Canadian Health Authority Approves THELIN (Sitaxsentan Sodium) for Pulmonary Arterial Hypertension; First Selective Endothelin A Receptor Antagonist, First Once-Daily Oral Treatment
- Actelion Announces Successful Study With Tracleer(R) in Patients With Mildly Symptomatic Pulmonary Arterial Hypertension
- Enhanced Coronary Calcification Determined By Electron Beam CT Is Strongly Related to Endothelial Dysfunction in Patients With Suspected Coronary Artery Disease*
- Actelion Launches Tracleer in PAH in Japan
- New Data Demonstrate Alvesco(R) (Ciclesonide) Significantly Improves Quality-of-Life for Patients With Mild-to-Moderate Asthma
 |
 |
User Comments (0)
RSS Feeds